(Q35601661)

9 August 2017

1 reference

title

Rationale for the use of bisphosphonates in osteoblastic and osteolytic bone lesions (English)

1 reference

9 August 2017

1 reference

Jean-Jacques Body

1

1 reference

9 August 2017

publication date

1 August 2003

1 reference

9 August 2017

1 reference

9 August 2017

volume

12 Suppl 2

1 reference

9 August 2017

page(s)

S37-44

1 reference

Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980162-5

7 January 2021

Current use of bisphosphonates in oncology. International Bone and Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980162-5

7 January 2021

Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980162-5

7 January 2021

Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980162-5

7 January 2021

The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980162-5

7 January 2021

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980162-5

7 January 2021

Osteolysis and cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980162-5

7 January 2021

Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980162-5

7 January 2021

Skeletal metastasis of prostate adenocarcinoma in rats: Morphometric analysis and role of parathyroid hormone-related protein

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980162-5

7 January 2021

Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980162-5

7 January 2021

Biology of osteoclast activation in cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980162-5

7 January 2021

Comparative evaluation of markers of bone resorption in patients with breast cancer-induced osteolysis before and after bisphosphonate therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980162-5

7 January 2021

Biochemical markers of bone metabolism reflect osteoclastic and osteoblastic activity in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980162-5

7 January 2021

The clinical use of bone resorption markers in patients with malignant bone disease

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980162-5

7 January 2021

Current and future directions in medical therapy: hypercalcemia

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980162-5

7 January 2021

Extracellular signal-regulated kinases and calcium channels are involved in the proliferative effect of bisphosphonates on osteoblastic cells in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980162-5

7 January 2021

Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980162-5

7 January 2021

Bisphosphonates in cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980162-5

7 January 2021

Bisphosphonates induce breast cancer cell death in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980162-5

7 January 2021

Bisphosphonates for cancer patients: why, how, and when?

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980162-5

7 January 2021

Markers of bone turnover for the management of patients with bone metastases from prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980162-5

7 January 2021

Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980162-5

7 January 2021

Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980162-5

7 January 2021

Preclinical studies with zoledronic acid and other bisphosphonates: impact on the bone microenvironment

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980162-5

7 January 2021

10.1016/S0960-9776(03)80162-5

Identifiers

DOI

1 reference

9 August 2017

1 reference